-
Beijing adjusts the reimbursement standards for basic medical insurance medical materials All individual expenses below 1,000 yuan are included
Time of Update: 2023-02-03
According to the website of the Beijing Municipal Medical Security Bureau, the Beijing Municipal Medical Security Bureau recently issued a notice on adjusting the reimbursement standards for medical materials for basic medical insurance.
-
In 2023, pharmaceutical companies will start "buying, buying, buying" again!
Time of Update: 2023-02-03
On the same day, Fengyuan Pharmaceutical disclosed its plan to acquire assets, and the company purchased 100% of the equity of Tigermed Technology held by Tigermed Biologics by issuing shares and raised supporting funds.
-
In 2023, the pharmaceutical industry after the change of senior management is worth waiting for!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Shortly after the beginning of 2023, the market reported that Hengrui Pharmaceutical, the "first brother of medicine", announced internally that Jiang Ningjun, who had been one of the founders of CStone Pharmaceutical, was appointed as the deputy general manager and chief strategy officer of Hengrui Pharmaceutical, and he was responsible for the company's clinical research and business development.
-
Domestic innovative medical device R&D and industrialization has entered the fast lane!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Driven by multiple advantages such as encouraging innovative medical devices, easing the marginal of centralized procurement policies, and supporting equipment renewal with financial discounted interest loans, the development of the domestic medical device industry is accelerating, and domestic medical devices have gradually begun to usher in a harvest period, and products are constantly on the market.
-
Domestic pharmaceutical companies are active in cross-border license-in, and these fields have become hot
Time of Update: 2023-02-03
In addition, it is worth mentioning that on November 15, 2022, Huadong Medicine also announced that its US partner ImmunoGen, Inc. has announced that its world's first (first-in-class) ADC drug ELAHERE (mirvetuximab soravtansine-gynx, R&D code: IMGN853, HDM2002) for the treatment of platinum-resistant ovarian cancer Obtained accelerated marketing approval from the US Food and Drug Administration (FDA).
-
2023 Shenzhen Medical Fair
Time of Update: 2023-02-03
cn/shenzhen Address: Room 1003, Building A, Twin Buildings, No. 668 Xin Brick Road, Songjiang District, Shanghai Contact number: 18721265877 Contact WeChat: shenzhenexpo Contact person: Mr. Shen The 40th Shenzhen International Medical Equipment Exhibition 2023 will be held in Shenzhen World Exhibition and Convention Center on August 29-31, covering medical electronics and medical film Like equipment, intelligent medical care, ward nursing and auxiliary equipment, medical dressings, in vitro diagnostic reagents, optical first aid, rehabilitation nursing and medical informatization, etc.
-
More than 100 million yuan of hypoglycemic drug market, ushered in another evaluated pharmaceutical company!
Time of Update: 2023-02-03
On January 5, Hanyu Pharmaceutical issued an announcement that the company received the "Drug Registration Certificate" issued by the State Medical Products Administration, and the company's hypoglycemic drug "vildagliptin tablets" was approved for marketing and deemed to have passed the consistency evaluation.
-
Shaanxi issued a rehabilitation guide manual for people infected with the new coronavirus
Time of Update: 2023-02-03
2. Major health problems and rehabilitation suggestions during the recovery period According to the World Health Organization's "Guidelines for Personal Recovery of New Coronary Pneumonia", combined with clinical observation and population surveys, people recovering from new coronavirus infection currently have the following health problems: shortness of breath, limited physical activity and exercise, decreased physical strength and fatigue, hoarseness and cough, swallowing problems, smell and taste problems, anxiety, depression and sleep problems, body pain, etc.
-
The ophthalmic treatment market has reached 210 billion yuan, and the track has ushered in nugget fever
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];The eye is a very important organ for humans, and as eye health becomes more and more important, the size of the ophthalmic medical market has begun to show a steady growth trend.
-
Recently, medical companies have been taking frequent actions! Busy with acquisition, construction of R&D bases...
Time of Update: 2023-02-03
On January 4, 2023, it was learned that Canon Medical plans to spend US$300 million to open a new subsidiary, Canon Healthcare USA, in the United States, aiming to strengthen its imaging business and focus sales and investments on the US market.
-
Future strategic planning of pharmaceutical companies, new drug research and development into the focus of development!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];On January 4, Genting Xinyao released its strategic plan for the next two years and beyond, the company will further transform into a comprehensive biopharmaceutical company, realize the whole industry chain layout, including strong independent R&D and licensing capabilities, clinical development capabilities, and large-scale production and commercialization capabilities.
-
Straight to the point! On January 10, 5 listed companies were investigated by institutions, including two pharmaceutical companies
Time of Update: 2023-02-02
On January 10, Qianhong Pharmaceutical received a total of 8 institutional surveys, including three major securities companies such as Ping An Securities, Orient Securities and Everbright Securities, as well as Liuhe Investment and Huisheng Fund.
-
Pfizer P drug "soul bargain" negotiations failed! Azvudine in health insurance: let more patients use it
Time of Update: 2023-02-02
In 2021, the famous scene of "soul haggling" where 700,000 sky-high drugs were cut to more than 30,000 yuan is still fresh in memory. According to the concept of the Medical Insurance Bureau that "ev
-
The National Health Commission issued the 14th Five-Year Plan for Emergency Medical Rescue
Time of Update: 2023-02-02
Health commissions of all provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps: In order to strengthen emergency medi
-
At the end of the year, how to avoid those pits that have been stepped on by the annual quality review analysis of products?
Time of Update: 2023-02-02
Unconsciously, the time has reached December 2022, and there is less than a week left in 2022, how to carry out the annual quality review and analysis of drugs efficiently? This article sorts out the
-
The output value of biomedical manufacturing continues to break through, and this field will usher in major benefits
Time of Update: 2023-02-02
Biomedical industry is China's strategic emerging industry key areas, at present, China's biomedical industry development has entered a new stage, in response to the new situation changes, many place
-
Chongqing launched a special campaign to stabilize the price and ensure the quality of epidemic-related drugs and medical supplies
Time of Update: 2023-02-02
On the 9th, the Chongqing Municipal Bureau of Market Regulation issued the "Special Work Plan for Stabilizing the Price and Quality of Epidemic-related Drugs and Medical Supplies", and further deploy
-
The closing day of "national talks": the negotiation of exclusive varieties of proprietary Chinese medicines is easy, the price of Pfizer P drugs is high, and the finale of PD-1!
Time of Update: 2023-02-02
On January 8, the four-day 2022 national health insurance negotiations came to an end. The representatives of the companies present today are still waiting for a number of blockbuster new drugs in th
-
The National Medical Security Administration exposed typical cases in the first phase of 2023
Time of Update: 2023-02-02
93 yuan 。 According to the Regulations on the Supervision and Administration of the Use of Medical Security Funds and the Service Agreement of Designated Medical Institutions of Qinghai Province, the local medical insurance department handled the following results: 1.
-
The construction of the standard system of pharmaceutical packaging materials in the Chinese Pharmacopoeia has entered an intensive publicity period, and the National Pharmacopoeia Commission has issued 3 more announcements!
Time of Update: 2023-02-02
cn Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua Nanli, Dongcheng District, Beijing Zip code: 100061 National Pharmacopoeia Commission 2023-01-04 identification QR code viewing attachment On January 4, the National Pharmacopoeia Commission announced the draft of two general standards for prefilled syringes, nine draft standards for general detection methods for prefilled syringes, and draft standards for the determination of insoluble particles in pharmaceutical packaging materials.
